Fig. 2From: Impact of Bevacizumab on parenchymal damage and functional recovery of the liver in patients with colorectal liver metastasesMeta-analyses on the association of preoperative bevacizumab treatment with parenchymal damage and posthepatectomy liver failure in patients with CLM. a Association of bevacizumab treatment with sinusoidal obstruction syndrome (SOS). b Association of bevacizumab treatment with hepatic fibrosis. c Association of bevacizumab treatment with posthepatectomy liver failureBack to article page